JP2010536388A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536388A5 JP2010536388A5 JP2010522134A JP2010522134A JP2010536388A5 JP 2010536388 A5 JP2010536388 A5 JP 2010536388A5 JP 2010522134 A JP2010522134 A JP 2010522134A JP 2010522134 A JP2010522134 A JP 2010522134A JP 2010536388 A5 JP2010536388 A5 JP 2010536388A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- compound
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 82
- 108091033319 polynucleotide Proteins 0.000 claims description 77
- 102000040430 polynucleotide Human genes 0.000 claims description 77
- 239000002157 polynucleotide Substances 0.000 claims description 77
- 229920001184 polypeptide Polymers 0.000 claims description 65
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 65
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 65
- 210000004027 cell Anatomy 0.000 claims description 64
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 57
- 239000012634 fragment Substances 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 47
- 210000004443 dendritic cell Anatomy 0.000 claims description 35
- 239000002243 precursor Substances 0.000 claims description 33
- 239000000427 antigen Substances 0.000 claims description 29
- 108091007433 antigens Proteins 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 21
- 230000009261 transgenic effect Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 238000004113 cell culture Methods 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 230000000890 antigenic effect Effects 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 7
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 6
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 6
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 6
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 241001442539 Plasmodium sp. Species 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 claims description 3
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 3
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 3
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 3
- 239000013566 allergen Substances 0.000 claims description 3
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 2
- 241000223960 Plasmodium falciparum Species 0.000 claims description 2
- 241000223810 Plasmodium vivax Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- -1 autoantigen Substances 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 101000763314 Homo sapiens Thrombomodulin Proteins 0.000 claims 1
- 102100026966 Thrombomodulin Human genes 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 210000001787 dendrite Anatomy 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 108050009406 C-type lectin-like Proteins 0.000 description 1
- 102000002086 C-type lectin-like Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96911807P | 2007-08-30 | 2007-08-30 | |
| US5286508P | 2008-05-13 | 2008-05-13 | |
| PCT/AU2008/001294 WO2009026660A1 (en) | 2007-08-30 | 2008-08-29 | Dendritic cell marker and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014150520A Division JP6095616B2 (ja) | 2007-08-30 | 2014-07-24 | 樹状細胞マーカーおよびその使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010536388A JP2010536388A (ja) | 2010-12-02 |
| JP2010536388A5 true JP2010536388A5 (enExample) | 2011-09-22 |
Family
ID=40386591
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010522134A Pending JP2010536388A (ja) | 2007-08-30 | 2008-08-29 | 樹状細胞マーカーおよびその使用法 |
| JP2014150520A Active JP6095616B2 (ja) | 2007-08-30 | 2014-07-24 | 樹状細胞マーカーおよびその使用法 |
| JP2016206463A Active JP6433470B2 (ja) | 2007-08-30 | 2016-10-21 | 樹状細胞マーカーおよびその使用法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014150520A Active JP6095616B2 (ja) | 2007-08-30 | 2014-07-24 | 樹状細胞マーカーおよびその使用法 |
| JP2016206463A Active JP6433470B2 (ja) | 2007-08-30 | 2016-10-21 | 樹状細胞マーカーおよびその使用法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8426565B2 (enExample) |
| EP (1) | EP2195346B1 (enExample) |
| JP (3) | JP2010536388A (enExample) |
| CN (1) | CN101970491A (enExample) |
| AU (1) | AU2008294074B2 (enExample) |
| BR (1) | BRPI0815848A2 (enExample) |
| CA (1) | CA2697448C (enExample) |
| IL (1) | IL204157A (enExample) |
| WO (1) | WO2009026660A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0815848A2 (pt) | 2007-08-30 | 2017-06-06 | The Burnet Inst | composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit. |
| US20110110861A1 (en) * | 2008-05-13 | 2011-05-12 | Mireille Hanna Lahoud | Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells |
| EP2424560A4 (en) * | 2009-03-23 | 2013-11-27 | Inst Medical W & E Hall | COMPOUNDS AND METHOD FOR MODULATING THE IMMUNE REACTION |
| PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| RU2612903C2 (ru) | 2010-08-02 | 2017-03-13 | Ридженерон Фармасьютикалз, Инк. | Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены |
| HUE068728T2 (hu) | 2011-08-05 | 2025-01-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| EP2568051A1 (en) | 2011-09-07 | 2013-03-13 | Stallergenes S.A. | Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy |
| PL2809150T3 (pl) * | 2012-02-01 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL |
| CN103483441A (zh) * | 2012-06-10 | 2014-01-01 | 复旦大学 | 恒河猴ny-eso-1蛋白、其编码基因及应用 |
| CN103720719B (zh) * | 2013-10-11 | 2016-07-06 | 长沙赢润生物技术有限公司 | 一项DC和Treg细胞治疗红斑狼疮的技术 |
| WO2015143406A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| RU2016141307A (ru) | 2014-03-21 | 2018-04-24 | Регенерон Фармасьютикалз, Инк. | Отличные от человека животные, которые вырабатывают однодоменные связывающие белки |
| CN104387453A (zh) * | 2014-12-08 | 2015-03-04 | 深圳市同康生物医药有限公司 | 树突状细胞靶向肽及编码基因及应用 |
| US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| EP3397645A1 (en) * | 2015-12-28 | 2018-11-07 | Innate Pharma | VARIABLE REGIONS FOR NKp46 BINDING PROTEINS |
| US11517627B2 (en) * | 2017-01-20 | 2022-12-06 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| US20210277354A1 (en) * | 2018-06-19 | 2021-09-09 | Fondazione Telethon | Production of engineered dendritic cells and uses thereof |
| US12233356B2 (en) | 2019-03-21 | 2025-02-25 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| SG11202109702QA (en) | 2019-03-21 | 2021-10-28 | Codiak Biosciences Inc | Extracellular vesicles for vaccine delivery |
| EP3956456A1 (en) | 2019-04-17 | 2022-02-23 | Codiak BioSciences, Inc. | Compositions of exosomes and aav |
| US20230181758A1 (en) | 2019-07-03 | 2023-06-15 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| IL272194A (en) * | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multi-target antibodies for use in the treatment of diseases |
| EP4117717A1 (en) | 2020-03-13 | 2023-01-18 | Codiak BioSciences, Inc. | Extracellular vesicles for treating neurological disorders |
| EP4121450A2 (en) | 2020-03-20 | 2023-01-25 | Codiak BioSciences, Inc. | Extracellular vesicles for therapy |
| EP4216993A2 (en) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Methods of producing extracellular vesicles |
| WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
| JP2023544614A (ja) * | 2020-10-05 | 2023-10-24 | モナッシュ ユニバーシティ | Ｃｌｅｃ９ａ抗体 |
| CN114563574B (zh) * | 2020-11-27 | 2025-03-04 | 中国科学院北京基因组研究所(国家生物信息中心) | 分子标记物组合及其用途 |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| WO2025079599A1 (ja) * | 2023-10-11 | 2025-04-17 | 国立大学法人金沢大学 | サブセットレベルで細胞を標的化可能な担体およびその製造方法 |
| CN119661686B (zh) * | 2024-09-30 | 2025-09-30 | 中国农业大学 | 一种重组clec9a基因及其在提高动物的免疫和抗病能力中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4542225A (en) | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5118606A (en) | 1988-09-02 | 1992-06-02 | The Regents Of The University Of California | Methods for detecting cellular pathology by assaying spectrin and spectrin breakdown products |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5536642A (en) * | 1993-09-09 | 1996-07-16 | Barbera-Guillem; Emilio | Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases |
| US5597569A (en) | 1993-10-25 | 1997-01-28 | Bristol-Myers Squibb Company | Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica |
| DE69536091D1 (de) | 1994-01-27 | 2010-09-09 | Univ Massachusetts Medical | Immunisierung durch Impfung von DNS Transkriptionseinheit |
| US6117985A (en) | 1995-06-16 | 2000-09-12 | Stemcell Technologies Inc. | Antibody compositions for preparing enriched cell preparations |
| US5939400A (en) | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
| AU3210997A (en) | 1996-05-24 | 1997-12-09 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| ES2374290T3 (es) | 1998-03-20 | 2012-02-15 | Commonwealth Scientific And Industrial Research Organisation | Genes sintéticos y constructos genéticos que comprenden los mismos. |
| EP1068311B2 (en) | 1998-04-08 | 2020-12-09 | Commonwealth Scientific and Industrial Research Organisation | Methods and means for obtaining modified phenotypes |
| EP1046651A1 (en) | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| AUPQ002399A0 (en) | 1999-04-28 | 1999-05-20 | Australian National University, The | Model membrane systems |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US20020132753A1 (en) | 2000-01-31 | 2002-09-19 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| US20030190598A1 (en) * | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| CA2459137A1 (en) | 2001-09-14 | 2003-03-27 | Incyte Genomics, Inc. | Receptors and membrane-associated proteins |
| CA2469941A1 (en) | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| WO2003091435A1 (fr) * | 2002-04-23 | 2003-11-06 | Riken | Nouvelles proteines et differents adn les codant |
| US6813008B2 (en) | 2002-06-10 | 2004-11-02 | Palantyr Research, Llc | Microdissection optical system |
| US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| WO2004108079A2 (en) | 2003-05-30 | 2004-12-16 | University Of Massachusetts | Parkin-interacting proteins |
| CN102172397B (zh) | 2003-08-21 | 2013-01-30 | 利普泰克有限公司 | 树突细胞的体内靶向 |
| ZA200604620B (en) * | 2003-12-10 | 2007-10-31 | Medarex Inc | IP-10 antibodies and their uses |
| CA2597431A1 (en) | 2005-02-11 | 2006-08-17 | Cambridge Scientific Pty Ltd | A method of producing an analgesic composition from plasma or serum and use in treating pain |
| US20070026047A1 (en) | 2005-06-21 | 2007-02-01 | Li-Chun Tsou | Thermal effect on crystalinity for drug delivery devices |
| CA2625403A1 (en) | 2005-10-17 | 2007-04-26 | Institute For System Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| BRPI0815848A2 (pt) | 2007-08-30 | 2017-06-06 | The Burnet Inst | composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit. |
| US20110110861A1 (en) | 2008-05-13 | 2011-05-12 | Mireille Hanna Lahoud | Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells |
| EP2424560A4 (en) | 2009-03-23 | 2013-11-27 | Inst Medical W & E Hall | COMPOUNDS AND METHOD FOR MODULATING THE IMMUNE REACTION |
-
2008
- 2008-08-29 BR BRPI0815848A patent/BRPI0815848A2/pt not_active Application Discontinuation
- 2008-08-29 CA CA2697448A patent/CA2697448C/en active Active
- 2008-08-29 JP JP2010522134A patent/JP2010536388A/ja active Pending
- 2008-08-29 EP EP08783037.8A patent/EP2195346B1/en active Active
- 2008-08-29 US US12/675,392 patent/US8426565B2/en active Active
- 2008-08-29 CN CN2008801106595A patent/CN101970491A/zh active Pending
- 2008-08-29 WO PCT/AU2008/001294 patent/WO2009026660A1/en not_active Ceased
- 2008-08-29 AU AU2008294074A patent/AU2008294074B2/en active Active
-
2010
- 2010-02-25 IL IL204157A patent/IL204157A/en active IP Right Grant
-
2013
- 2013-03-21 US US13/848,503 patent/US9988431B2/en active Active
-
2014
- 2014-07-24 JP JP2014150520A patent/JP6095616B2/ja active Active
-
2016
- 2016-10-21 JP JP2016206463A patent/JP6433470B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010536388A5 (enExample) | ||
| US11939374B2 (en) | Treatment of fibrosis | |
| JP2023106392A (ja) | Ｃｄ３抗原結合性断片及びその使用 | |
| WO2022199590A1 (zh) | 一种靶向bcma的纳米抗体及其应用 | |
| JP2023179450A (ja) | 抗－ヒトプログラム細胞死リガンド－１（ｐｄ－ｌ１）の抗体及びその用途 | |
| EP4025909A1 (en) | Methods for identification of antigen binding specificity of antibodies | |
| AU2014236867A1 (en) | Methods and compositions relating to anti-CCR7 antigen binding proteins | |
| CN110872353B (zh) | 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用 | |
| WO2024017362A1 (zh) | 靶向gprc5d和/或bcma的嵌合抗原受体及其应用 | |
| CN113583124B (zh) | 一种抗前胃泌素释放肽单克隆抗体及其制备方法 | |
| CN101706507B (zh) | 用异硫氰酸荧光素标记的抗人cd45ra单抗的应用 | |
| CN117843788A (zh) | 一种抗gprc5d的抗体及其多特异性抗体和相关应用 | |
| TW202019482A (zh) | Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法 | |
| US11180544B2 (en) | Method of producing antibody fragment | |
| CN116444663A (zh) | 乙型脑炎病毒抗体及其应用 | |
| CN116589571A (zh) | 乙型脑炎病毒抗体及其应用 | |
| CN116333149A (zh) | 一种结合pcsk9抗原的单域抗体及其制备方法 | |
| CN120040594A (zh) | 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用 | |
| CN114773485A (zh) | 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子 |